{"slug":"ovarian","tag":"ovarian","variants":["ovarian"],"description":"No description yet","count":12,"kinds":{"person":12},"related":[{"slug":"parp","tag":"parp","shared":4},{"slug":"trialist","tag":"trialist","shared":4},{"slug":"cooperative-group","tag":"cooperative-group","shared":3},{"slug":"surgery","tag":"surgery","shared":3},{"slug":"adc","tag":"adc","shared":2},{"slug":"cervical","tag":"cervical","shared":2},{"slug":"gynaecological","tag":"gynaecological","shared":2},{"slug":"early-detection","tag":"early-detection","shared":1},{"slug":"endometrial","tag":"endometrial","shared":1},{"slug":"hipec","tag":"hipec","shared":1},{"slug":"hrd","tag":"hrd","shared":1},{"slug":"screening","tag":"screening","shared":1}],"records":[{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","route":"/people/kathleen-moore/","tldr":"Led SOLO-1 and MIRASOL, which gave ovarian cancer a maintenance PARP inhibitor and its first ADC with a survival benefit."},{"id":"isabelle-ray-coquard","kind":"person","name":"Isabelle Ray-Coquard","route":"/people/isabelle-ray-coquard/","tldr":"Led PAOLA-1, which showed olaparib plus bevacizumab helps women with HRD-positive ovarian cancer beyond BRCA carriers."},{"id":"jonathan-ledermann","kind":"person","name":"Jonathan A. Ledermann","route":"/people/jonathan-ledermann/","tldr":"Led Study 19, the trial that first showed PARP inhibitor maintenance works in ovarian cancer."},{"id":"robert-coleman","kind":"person","name":"Robert L. Coleman","route":"/people/robert-coleman/","tldr":"Gynaecologic oncologist who led ARIEL3 and GOG-0213, shaping PARP maintenance and secondary surgery in relapsed ovarian cancer."},{"id":"andreas-du-bois","kind":"person","name":"Andreas du Bois","route":"/people/andreas-du-bois/","tldr":"Surgeon who chairs the German AGO group and led DESKTOP III, proving secondary surgery can extend survival in selected relapsed ovarian cancer."},{"id":"willemien-van-driel","kind":"person","name":"Willemien J. van Driel","route":"/people/willemien-van-driel/","tldr":"Led OVHIPEC-1, the trial that showed heated intraperitoneal chemotherapy at surgery extends survival in ovarian cancer."},{"id":"ignace-vergote","kind":"person","name":"Ignace Vergote","route":"/people/ignace-vergote/","tldr":"Led the EORTC trial that made neoadjuvant chemotherapy acceptable in ovarian cancer and innovaTV 301, the first ADC survival win in cervical cancer."},{"id":"usha-menon","kind":"person","name":"Usha Menon","route":"/people/usha-menon/","tldr":"Led UKCTOCS, the 200,000-woman trial that found ovarian cancer screening does not save lives despite detecting cancers earlier."},{"id":"mansoor-raza-mirza","kind":"person","name":"Mansoor Raza Mirza","route":"/people/mansoor-raza-mirza/","tldr":"Led NOVA and RUBY, the trials that established niraparib maintenance in ovarian cancer and dostarlimab in advanced endometrial cancer."},{"id":"bradley-monk","kind":"person","name":"Bradley J. Monk","route":"/people/bradley-monk/","tldr":"Gynaecologic oncologist who co-led KEYNOTE-826, innovaTV 301 and KEYNOTE-A18, the trials that rebuilt cervical cancer treatment."},{"id":"david-gershenson","kind":"person","name":"David M. Gershenson","route":"/people/david-gershenson/","tldr":"Houston gynaecologic oncologist who defined low-grade serous ovarian cancer as a distinct disease and led GOG 281, the trial that showed the MEK inhibitor trametinib works better than standard treatments for it."},{"id":"susana-banerjee","kind":"person","name":"Susana Banerjee","route":"/people/susana-banerjee/","tldr":"London gynaecological oncologist who led RAMP 201, the trial that established the avutometinib and defactinib combination for recurrent KRAS-mutant low-grade serous ovarian cancer."}]}